Know Fibromyalgia.

What it is

Fibromyalgia is a long-term condition where the body's pain processing system becomes turned up. Pain signals are amplified, ordinary touch can feel painful, and the nervous system stays in a low-grade alarm state most of the time. Alongside the pain, people live with deep fatigue, broken sleep, and a cognitive slowing widely called "fibro fog."

The clinical term for this category of illness is nociplastic pain, formally proposed by the International Association for the Study of Pain in 2016 and adopted as a third mechanistic category in 2017 (Kosek et al., 2016) . That's a third category of pain alongside nociceptive pain (from tissue damage) and neuropathic pain (from nerve damage). Fibromyalgia is the textbook example.

Fibromyalgia is not in the mind. It is not laziness. It is not a sign of weakness. It is a real, measurable change in how the central nervous system processes signals, with growing biomarker evidence to back it up (Gracely et al., 2002) (Albrecht et al., 2019) (Goebel et al., 2021) .

Where fibromyalgia sits among pain types

Pain medicine recognises three mechanisms. Knowing which one you're dealing with changes treatment.

Disease overview

Fibromyalgia is a chronic, relapsing illness. Symptoms can flare and settle, sometimes triggered by an obvious event like infection, surgery, or emotional stress, sometimes without warning. For most people it is lifelong, though many find a baseline they can work with through pacing, sleep care, gentle movement, and the right medical support.

Clinical reviews often describe fibromyalgia as "non-progressive." Many patients dispute this from lived experience.

It often arrives alongside other conditions. ME/CFS, POTS, IBS, migraine, endometriosis, and small fibre neuropathy show up so often that researchers increasingly view fibromyalgia as one expression of a broader central sensitivity syndrome family.

Core symptoms

Severity, and why two people with the same diagnosis can live very different lives

Fibromyalgia exists on a wide spectrum.

Causes and biological mechanisms

Fibromyalgia has no single cause. The current scientific picture points to a combination of:

• Central sensitisation. The brain and spinal cord amplify pain signals. Functional MRI shows that fibromyalgia patients activate pain-processing regions in response to pressure that healthy controls describe as merely uncomfortable (Gracely et al., 2002) .
• Small fibre neuropathy. Skin biopsies in roughly 40 to 50% of fibromyalgia patients show reduced small nerve fibre density, providing a peripheral substrate for the pain (Oaklander et al., 2013) (Üçeyler et al., 2013) .
• Autonomic dysfunction. The autonomic nervous system, which controls heart rate, blood pressure, digestion, and temperature, is dysregulated in most patients. This explains the dizziness, gut symptoms, and temperature swings.
• Neuroinflammation. PET imaging by Albrecht and colleagues found elevated glial activation throughout the brain in fibromyalgia patients, evidence of low-grade neuroinflammation (Albrecht et al., 2019) .
• HPA axis dysregulation. The body's stress-response system runs abnormally. Cortisol patterns are blunted in many patients.
• Possible autoimmune component. The Goebel transfer study showed that IgG antibodies from fibromyalgia patients, injected into mice, produced fibromyalgia-like symptoms (Goebel et al., 2021) ; a 2023 follow-up identified satellite-glial-cell targets (Krock et al., 2023) . This is currently the strongest evidence for an autoimmune contribution in at least a subset of patients.
• Genetic predisposition. First-degree relatives have an 8 times higher risk. Polymorphisms in genes for serotonin transport, catecholamine metabolism, and sodium channels have all been implicated.
• Triggering events. Viral infections (Epstein-Barr, COVID-19), physical trauma (car accidents, surgery), childbirth, severe emotional stress, and prolonged sleep deprivation can all precipitate onset.

Fibromyalgia in men

10–20% of diagnosed patients are men. The true number is almost certainly higher, male presentations get misread as "muscle strain," "stress," "depression," or "just getting older" more often than female ones. Men also wait longer for diagnosis on average.

The clinical picture is largely the same, but with a few patterns that show up more in men:

• Pelvic and genitourinary symptoms. Painful erections, erectile dysfunction, testicular pain without urological findings, and pelvic-floor muscle tension are commonly reported by men with fibromyalgia and almost never asked about by clinicians.
• Job-loss as the first sign of severity. Cultural pressure to "push through" delays men from naming the symptoms. The crash often comes as inability to continue physically-demanding work.
• Under-treatment of mental health. Depression and anxiety in men with fibromyalgia are flagged later, treated less.

Pediatric and juvenile fibromyalgia

Juvenile fibromyalgia is real and routinely missed. Onset before age 18 is more common than the published literature suggests, partly because the diagnosis is often only made years later, partly because children are routinely told their pain is normal.

Patterns to take seriously:

• "Growing pains" that don't go away. Persistent or migrating pain throughout childhood that is repeatedly normalised.
• The high-achiever who suddenly crashes. Often a teenager who has been masking for years. The crash comes at the end of an exam term, after a sports season, or after a viral illness.
• Comorbid migraines, IBS, dysmenorrhoea. These often appear before the pain-amplification picture becomes obvious.
• Triggers in childhood. Chronic infections (strep, EBV, scarlet fever, mono), concussions, and significant adverse childhood experiences are all over-represented in the histories of adult fibromyalgia patients.

Pediatric fibro responds well to pacing, sleep care, and gentle movement, and badly to being told it's anxiety or "trying to get out of school." A clinician familiar with juvenile chronic pain (rheumatology or pain medicine) is worth driving for.

Related conditions and overlaps

Fibromyalgia rarely travels alone. Roughly 50 to 70% of people with fibromyalgia also meet criteria for at least one of: ME/CFS, IBS, migraine, POTS, TMJ disorder, interstitial cystitis, restless legs syndrome, endometriosis, or anxiety. Chapter six covers each of these in more depth.

Support for family and loved ones

One of the hardest parts of fibromyalgia is that the people around the patient cannot see the illness. The pain has no rash, the fatigue has no cast, and the brain fog does not show up in conversation until it is too late to mask. Loved ones who want to help often start by trying to fix things. The most helpful posture is different: believe the patient, take cancellations gracefully, and treat pacing not as withdrawal but as the work of staying functional.

Specific things that help: shorter visits, plans with built-in escape hatches, doing the cognitive labour of remembering medications and appointments, taking on driving on bad days, and being the person who reminds the patient that the illness is not their fault. Specific things that hurt: unsolicited cures, suggestions to try yoga or "just push through," and treating good days as proof that the illness was overstated.

Living with an invisible illness

Fibromyalgia is one of the most invisible illnesses in modern medicine. There is no rash, no swelling, no cast, no blood test that comes back red. Patients look fine. That gap between how someone looks and how they feel is the dominant social and emotional reality of the disease.

The cost of invisibility is steep. Family members forget. Employers doubt. Doctors miss the diagnosis. Patients learn to mask, to push through, and to apologise for being unreliable. Over time, many internalise the doubt of others and stop reporting their own symptoms accurately.

Medical gaslighting

Few illnesses are as associated with medical gaslighting as fibromyalgia. For most of the 20th century, fibromyalgia was openly dismissed as psychosomatic, a "wastebasket diagnosis," or a manifestation of depression. That history has not fully washed out.

Dismissal is not a soft harm. Patients who are told their symptoms are imagined stop reporting them, stop seeking care, and get worse. Decades of qualitative research document that clinician disbelief is one of the strongest predictors of poor outcomes in fibromyalgia and adjacent conditions (Doebl et al., 2020) (Choy et al., 2010) .

The pattern is still active in 2025. Patients today still hear lines like this:

A short history of who was wrong, and when

It helps to name the timeline, because the dismissal patients still encounter is downstream of specific decisions in specific decades.

• 1904. Sir William Gowers coins "fibrositis," attributing chronic muscle pain to inflammation. The inflammation theory was wrong, but the clinical picture matched modern fibromyalgia.
• Mid-20th century. Psychiatry absorbs the syndrome under labels like "psychogenic rheumatism." Patients are routinely told the pain is depression in disguise.
• 1976. The term "fibromyalgia" replaces "fibrositis," reflecting that the inflammation model was wrong, but not yet that the centre of the action is the nervous system.
• 1990. The American College of Rheumatology publishes the first formal classification criteria. Fibromyalgia is recognised as a clinical entity. Still widely dismissed by individual clinicians.
• 2002. Gracely and colleagues publish fMRI evidence of augmented pain processing in fibromyalgia patients (Gracely et al., 2002) . Central sensitisation gains a measurable substrate.
• 2013. Oaklander shows ~40% of fibromyalgia patients have measurable small fibre neuropathy on skin biopsy (Oaklander et al., 2013) . A peripheral biological substrate, on top of the central one.
• 2017. The IASP formally adopts nociplastic pain as a third pain category, with fibromyalgia as the canonical example (Kosek et al., 2016) .
• 2019. Albrecht's PET imaging shows widespread glial activation across the brain in fibromyalgia, direct evidence of neuroinflammation (Albrecht et al., 2019) .
• 2021. Goebel transfers IgG antibodies from fibromyalgia patients to mice. The mice develop fibromyalgia-like symptoms (Goebel et al., 2021) . A subset of fibromyalgia is autoimmune.
• 2021. NICE formally withdraws its recommendation of graded exercise therapy for ME/CFS (NICE, 2021) , repudiating the rigid version of GET still being prescribed to many fibromyalgia patients with significant post-exertional malaise overlap.

The science has moved. The clinical culture, in many places, has not.

Impact on identity

Most patients describe a "before" self and an "after" self. The transition involves grieving the version of themselves who could work full days, travel without planning, parent without rationing energy, and exercise without paying for it. Identity work, the process of building a self that includes the illness rather than fighting it, is some of the hardest, most private work of the illness.

Social isolation

Pacing means cancelling. Cancelling enough times means invitations stop. Patients describe friendships fading not because of conflict but because of accumulated absences. Many move toward online communities of other patients, which are often more sustaining than in-person social ties.

Mental health

Depression and anxiety are common in fibromyalgia, with prevalence estimates of 30 to 60%. The historical assumption was that depression caused fibromyalgia. The current evidence runs the other way: living with chronic, dismissed pain produces depression and anxiety as natural consequences. Both deserve treatment in their own right, but treating only the depression rarely resolves the fibromyalgia.

Patient voices

Fibromyalgia touches almost every body system. The list below is comprehensive, not a checklist. No patient has every symptom, and patterns shift over time and during flares.

Neurological

Brain fog

The dominant cognitive symptom. Slowed thinking, word-finding difficulty, losing the thread of a sentence mid-sentence, forgetting why you walked into a room. Often worse during flares, after physical exertion, after sleep deprivation, and in noisy environments.

Brain fog during a normal conversation

Both are true. The outside view is what observers see; the inside view is what's happening.

Memory impairment

Short-term and working memory are most affected. Long-term memory is generally preserved. Patients often compensate with lists, alarms, and routines.

Slowed processing speed

Neuropsychological testing in fibromyalgia patients shows reduced processing speed on par with someone roughly 20 years older. This is real, measurable, and not "just stress."

Sensory hypersensitivity

Bright lights, loud sounds, strong smells, certain fabrics, perfumes, and even some foods can trigger flares. The nervous system has lost the ability to filter noise from signal.

Neuroinflammation

PET imaging studies show elevated glial cell activation across the brain in fibromyalgia (Albrecht et al., 2019) . This is one of the strongest objective biological findings in the field.

Autonomic and dysautonomia

Orthostatic intolerance and POTS overlap

Roughly a third of fibromyalgia patients have meaningful orthostatic intolerance. When they stand, blood pressure drops, heart rate spikes, or both, producing dizziness, lightheadedness, palpitations, and brain fog. A subset meet full criteria for POTS.

Reduced cerebral blood flow

Some studies show reduced blood flow to specific brain regions during cognitive tasks, helping explain the cognitive symptoms.

Air hunger

The sensation of not getting enough air despite normal oxygen saturation. Common in flares.

Temperature regulation problems

Cold hands and feet, intolerance to heat, night sweats, and trouble adjusting to weather changes. Raynaud's phenomenon shows up in roughly 30% of patients. A frequently reported variant: a "fibro fever" sensation with no measurable temperature rise.

Sweating abnormalities

Either too much or too little. Often patchy. Linked to the small fibre nerves that control sweat glands.

GI dysfunction

IBS-type symptoms appear in 30 to 70% of patients: bloating, alternating constipation and diarrhoea, food sensitivities, and post-meal fatigue. Gastroparesis is also more common.

Note: post-exertional malaise isn't only physical

For patients in the fibromyalgia / ME-CFS overlap, the trigger for a crash isn't always exertion in the way the word implies, mental, social, and emotional load can produce the same delayed worsening as a long walk.

Immune

Flu-like symptoms

Many patients describe flares as "feeling like the flu without the flu": body aches, low-grade malaise, swollen-feeling lymph nodes, and a sense of being unwell. Often there is no fever.

Cytokine abnormalities

Multiple studies have found elevated levels of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) in fibromyalgia. Not high enough to flag a classic inflammatory disease, but high enough to suggest a chronically activated immune system.

Viral reactivation

Epstein-Barr virus, HHV-6, and other latent viruses are more frequently reactivated in fibromyalgia patients. The role this plays in symptom severity is still being studied, particularly in the post-COVID era.

Mast cell activation

A subset of patients have overlapping Mast Cell Activation Syndrome, which produces histamine-driven symptoms (flushing, hives, GI distress, food and drug sensitivities) on top of the fibromyalgia.

Autoantibodies

Goebel and colleagues showed that IgG antibodies from fibromyalgia patients, transferred to mice, produced fibromyalgia-like symptoms (Goebel et al., 2021) . This is the strongest evidence to date that an autoimmune mechanism contributes in at least a subset of patients.

Pain

Fibromyalgia pain is rarely fixed in one place. It migrates day to day. That single feature is one of the strongest clinical signals that what you're looking at isn't arthritis.

Muscle pain

Diffuse, aching, often described as "feeling like you have the flu, in your muscles, all the time." Worse with cold, fatigue, and sustained postures.

Joint pain without joint damage

Pain feels arthritic, but X-rays and inflammatory markers are usually normal. This often leads to misdiagnosis or delayed diagnosis.

Neuropathic pain

Burning, electric, tingling, or numb sensations. Often correlated with small fibre neuropathy findings on skin biopsy (Oaklander et al., 2013) .

Chest pain

Costochondritis (inflammation of the rib cartilage) is common and frequently mistaken for cardiac pain. Many fibromyalgia patients have visited the ER for chest pain at least once.

Allodynia and hyperalgesia

Allodynia: pain from things that should not hurt (a hug, a waistband, a bedsheet). Hyperalgesia: more pain than a stimulus should produce. Both are hallmark features.

Weather and barometric sensitivity

Some patients can predict storms. Pressure changes precede flares in a meaningful subset, sometimes by 24 hours.

A bad pain day

Sleep

Unrefreshing sleep

The single most consistent symptom alongside pain. Patients sleep but do not wake recovered.

Disrupted sleep architecture

EEG studies show alpha wave intrusion into delta (deep) sleep, first documented by Moldofsky and colleagues in 1975 (Moldofsky et al., 1975) . The brain stays partially awake during what should be the most restorative phase. Inducing the same pattern in healthy volunteers reproduces fibromyalgia-like symptoms, suggesting sleep disruption is not just a consequence but a driver.

Insomnia and delayed sleep phase

Difficulty falling asleep, difficulty staying asleep, and a tendency for the body clock to drift later are all common. A particular pattern, the "wired-and-tired" night, comes up over and over in patient communities and seems distinct from ordinary insomnia.

Sleep bruxism (teeth grinding)

Highly prevalent in fibromyalgia and contributes to TMJ pain and unrefreshing sleep. Often unnoticed by the patient, a partner or dentist usually spots it first. A night guard is the simplest first intervention.

Hypersomnia

Particularly during flares, some patients sleep 12 to 16 hours and still wake exhausted.

Restless legs and periodic limb movements

Affect roughly a third of patients, further fragmenting sleep.

Sleep apnea overlap

Co-occurs more often than chance. Worth ruling out, since treating apnea can significantly improve fibromyalgia symptoms.

Vision and hearing

Dry eyes

Very common, often the first sicca symptom, sometimes the first sign of overlapping Sjögren's. Frequent blinking, gritty sensation, sensitivity to wind and screens. Worth flagging to your GP and an ophthalmologist; preservative-free artificial tears are the basic intervention.

Blurry vision and prescription drift

Vision can blur during flares and fog episodes. Sometimes this is the brain (cognitive narrowing); sometimes it's a fixable prescription change. Get re-tested before assuming it's "just fibro."

Tunnel vision under cognitive load

A common but under-investigated pattern: the visual field feels narrower under stress or fog, as if you're looking through a paper-towel tube. Different from acute visual loss, comes and goes with cognitive state.

Tinnitus and sound sensitivity

Persistent ringing in one or both ears (tinnitus) and intolerance to loud or sudden sounds (hyperacusis) are both common. They often worsen during flares. Audiology workup is reasonable; protection (noise-cancelling headphones, soft earplugs at concerts) helps day-to-day.

Oral and dental

The mouth gets hit on multiple fronts. Bruxism (already discussed under sleep) drives TMJ pain. Dry mouth is common, from medications, from autonomic dysfunction, and from overlapping sicca. Burning mouth syndrome appears in a subset. Gums can bleed more easily, dental caries can climb despite good hygiene because saliva is doing less work. Six-monthly dental visits matter more than they used to.

Sexual and reproductive symptoms

Almost never asked about clinically; reported in almost every long thread on patient forums.

Libido

Often dramatically reduced, not from psychological aversion but from whole-body energy conservation. Distinct from depression-driven libido loss, though it can co-occur.

Pain during sex

Dyspareunia is more common than in age-matched controls, with multiple drivers: pelvic-floor hypertonicity, sicca, allodynia in genital/perineal skin, overlapping endometriosis. Treatable, usually with a pelvic-floor physical therapist as the first stop.

Male sexual dysfunction

Painful erections, erectile dysfunction, and persistent testicular/perineal pain without urological cause are reported but rarely studied. Worth raising even if it feels off-topic for a rheumatology appointment.

Menstrual and reproductive

Premenstrual and menstrual weeks are usually flares. Perimenopause is often the worst period for symptom severity. Pregnancy goes either way, some patients improve, some flare; postpartum is high-risk for new or worsening fibromyalgia.

Vestibular and proprioception

Vertigo and balance disturbance

Distinct from orthostatic dizziness (which is autonomic). True vertigo episodes, the room spinning, often with nausea, show up in a subset, sometimes worsened by neck or temporomandibular dysfunction.

Clumsiness and bumping into things

Proprioception, your brain's awareness of where your body is in space, is degraded in many fibro patients. Doorframes, table edges, dropped objects. Often unfairly written off as carelessness or fog.

Weight and body composition

Weight changes are bidirectional. Sedentary periods + medications like pregabalin and amitriptyline can drive significant weight gain. IBS overlap, low appetite during flares, and severe gut symptoms can drive weight loss. Either direction can be distressing and is largely outside the patient's direct control, body shaming makes it worse.

How diagnosis is made

Fibromyalgia is a clinical diagnosis. There is no blood test, no scan, no biopsy that confirms it. Diagnosis is made by a clinician who applies the established criteria, takes a thorough history, examines the patient, and rules out other conditions that could explain the symptoms.

Diagnostic criteria

The 2016 revision of the American College of Rheumatology criteria is the most widely used today (Wolfe et al., 2016) . A patient meets criteria when all of the following are true:

• Widespread Pain Index (WPI) of 7 or more and Symptom Severity Scale (SSS) of 5 or more, or WPI of 4 to 6 and SSS of 9 or more.
• Generalised pain, defined as pain in at least four of five body regions, present for at least three months.
• The diagnosis is valid regardless of whether the patient has another condition. Fibromyalgia can coexist with other diseases.

The older tender point exam (introduced in 1990) is no longer required. It is still sometimes used as supporting evidence but is not part of current criteria.

Tests to rule out other diseases

Fibromyalgia is partly a diagnosis of exclusion. The following tests are typically ordered to rule out conditions that can mimic it:

Differential diagnosis

The most common conditions that look like fibromyalgia but are not (or are co-occurring):

• Hypothyroidism, particularly Hashimoto's
• Early rheumatoid arthritis, lupus, polymyalgia rheumatica, ankylosing spondylitis
• Vitamin D and B12 deficiency
• Obstructive sleep apnea
• ME/CFS (overlapping but distinct, particularly around post-exertional malaise)
• Major depressive disorder with somatic symptoms
• Hyperparathyroidism
• Lyme disease and other tick-borne infections (where regionally relevant)
• Multiple sclerosis (in cases with significant neuropathic features)

Mimics that aren't always ruled out

Some conditions produce widespread or migratory pain that overlaps with fibromyalgia closely enough to be mistaken for it, and they're not in the standard differential most rheumatologists run. A few worth raising with a clinician if symptoms are predominantly left-sided, lower-body, or vascular-pattern:

• Vascular venous compression syndromes, May-Thurner Syndrome (left iliac vein), Pelvic Congestion Syndrome, Nutcracker Syndrome (left renal vein). Often diagnosed by a vascular surgeon rather than a rheumatologist.
• Thoracic Outlet Syndrome (vTOS / nTOS). Arterial or nerve compression at the collarbone / first rib. Produces upper-body pain often labelled fibro.
• Cervical instability in hypermobile EDS. Pain referred from cervical structural issues.

None of these rules out a fibromyalgia diagnosis. They're worth investigating in parallel, especially in patients who don't respond as expected to first-line treatment.

A note on diagnostic delay

Many adults with fibromyalgia were children with fibromyalgia, and were told it was something else.

Finding the right clinician

The single most predictive factor of good outcomes in fibromyalgia is finding a clinician who treats the diagnosis as real. If your first rheumatologist refuses further workup, second opinions matter, and there's a practical wrinkle worth knowing.

What to say (and not say) at a doctor's appointment

The way you describe your symptoms changes whether a clinician takes them seriously. The patient community has converged on a few patterns that consistently work, and a few that almost always backfire. Below is the distilled version. There's also a downloadable appointment script you can bring with you.

Treatment framework

There is no cure for fibromyalgia. The goal of treatment is to reduce symptom severity, improve sleep, restore function, and rebuild a sustainable rhythm of daily life. The best outcomes come from combining several approaches rather than relying on a single one, the European Alliance of Associations for Rheumatology (EULAR) revised recommendations and subsequent national guidelines all converge on multimodal, non-pharmacological-first management with medications added when needed (Macfarlane et al., 2017) (Häuser et al., 2017) .

Pacing and energy management

Pacing is the foundational self-management strategy in fibromyalgia, ME/CFS, and Long COVID. The idea is to operate within an "energy envelope," doing enough to live a meaningful life but stopping before exertion triggers a flare.

Practical pacing looks like:

• Knowing your baseline. The amount of activity you can do most days without a flare.
• Working in short blocks with planned rests, even on good days.
• Anticipating that good days are the most dangerous, because they invite overexertion.
• Treating rest as a deliberate intervention, not a failure.
• Using heart rate, HRV, sleep data, or symptom logs to spot drift before a crash.

Wearable pacing tools (the Visible armband is a common one in patient communities; Oura, Apple Watch, and Whoop are used similarly) reveal something patients often don't see for themselves, how much energy "small" tasks actually cost.

Three concrete pacing protocols, with worked examples

Pacing is the single highest-leverage non-drug intervention in fibromyalgia, ME/CFS, and Long COVID. The advice you'll usually hear ("don't overdo it") is useless without a method. Modern pacing frameworks have moved well beyond simple "just rest", the goal is sustainable consistency, not minimum activity (Antcliff et al., 2018) . Patients who succeed at pacing pick a concrete protocol, usually one of these three, and stick to it long enough to recalibrate.

1) Heart-rate ceiling

Used widely in ME/CFS communities; works well for fibro patients with significant post-exertional malaise. The rule: keep your heart rate below a personal threshold for most of the day. A common starting formula is (220 − your age) × 0.6. Your wearable beeps when you cross it.

Worked example. A 38-year-old patient sets a ceiling of (220−38) × 0.6 ≈ 109 bpm. They wear an Apple Watch with an alert. Climbing stairs slowly: under. Cooking standing up: just under. Carrying groceries up two flights: 130 bpm, over. The watch buzzes; they put the bags down, sit for two minutes, and resume slowly. After 4–6 weeks, the threshold can usually rise without triggering a crash. After 6 months of consistency, many patients no longer need the wearable, the body's sense of the limit has come back.

2) Time-budget blocks

Used widely in fibromyalgia communities; works well when symptoms are pain-dominant rather than energy-dominant. The rule: work in 25–45 minute blocks with 10–20 minute rests, even on good days. Rests are mandatory, not earned. Activities are stacked so that high-cost tasks (cleaning, errands) are followed by genuine recovery (lying flat, dim room), not just sitting at a screen.

Worked example. A patient with moderate fibro schedules a Saturday: 30 min cooking → 15 min lying down with eyes closed → 30 min folding laundry → 15 min lying down → 45 min coffee with a friend → 30 min lying down → 30 min admin. Total active time: 2.25 hours. They feel productive. They don't crash on Sunday. The previous Saturday, without blocks, "powering through", they were bed-bound from Monday to Wednesday.

3) Energy envelope

Best for patients with day-to-day variability so high that fixed timing doesn't work. The rule: budget your day in units of "spoons," and track what each activity actually costs you. Stop when the envelope is empty, even if it's noon. Christine Miserandino's Spoon Theory (2003) is the original frame; modern apps and Rox automate the accounting.

Worked example. A patient starts a moderate day with 12 spoons. Shower = 2. Breakfast = 1. School run = 2. Email + one meeting = 3. They're at 8 spent before lunch. They cancel the optional 3 p.m. coffee (saves 2). They cook a simple dinner (1) and lie down by 7 (1). Total: 12. They sleep okay. They have 12 spoons again tomorrow, the envelope stays intact because they didn't borrow against it.

Tools and apps patients actually use

Most fibromyalgia self-management lives outside the doctor's office. Patients build their own toolkits from wearables, tracking apps, and (increasingly) AI tools that turn raw data into something actionable. Here's the practical landscape as of 2026.

Your AI companion for chronic illness

Rox

Living with fibromyalgia is a full-time job. Rox does the tracking, the remembering, and the pattern-finding, so you can spend your energy on living, not managing.

A companion that learns you. Log a symptom in a tap. Track your meds without thinking about it. Rox connects what you feel to your sleep, your wearable, your cycle and your meds, and quietly warns you days before a flare, so you can pace ahead of it instead of crashing into it.

Always there, no effort

Log pain, fatigue, fog, sleep or mood in one tap. Rox remembers everything so brain fog doesn't have to. Exportable for any doctor visit.

Your meds, working for you

What you take, when, dose, side effects, and whether each one is actually helping. The pattern most rheumatologists don't have time to find.

Triggers that are yours, not generic

Connects flares to your sleep, weather, food, exertion, cycle, glucose and meds. Plain-language insights, only when there's something real to tell you.

A heads-up before a flare

Reads HRV, sleep and resting heart rate from your Apple Watch, Oura, Whoop or Fitbit and flags drift 24–72 hours before you'd otherwise crash.

Meet Rox → Built for fibromyalgia, ME/CFS, POTS, MCAS and Long COVID · Works with the wearable you already own · Free to start

Sleep

Fixing sleep is often the single highest-leverage intervention. Standard sleep hygiene helps but is rarely sufficient on its own. Medications used to support sleep in fibromyalgia include low-dose amitriptyline, nortriptyline, cyclobenzaprine, trazodone, and (selectively) low-dose mirtazapine. Melatonin has modest evidence. Benzodiazepines and Z-drugs are generally avoided because they disrupt deep sleep architecture and have addiction risk.

Medications

Three medications carry FDA approval specifically for fibromyalgia. None of them work for everyone, and side effects are common. Most patients try several before finding what helps.

Other commonly used medications, off-label but evidence-supported:

• Low-dose amitriptyline. Old, cheap, and one of the most consistently effective for sleep and pain at doses of 10 to 25 mg at night.
• Cyclobenzaprine. A muscle relaxant used at low doses for sleep and morning stiffness.
• Gabapentin. Used similarly to pregabalin.
• Low-dose naltrexone (LDN). A growing body of evidence supports LDN at 1.5 to 4.5 mg for fibromyalgia pain, possibly through anti-neuroinflammatory effects on microglia (Younger et al., 2013) . Still off-label and not universally available.
• Tramadol. Used cautiously due to dependence and seizure risk. Opioids in general are not recommended for fibromyalgia.

Movement

Movement helps. The catch: most patients have been told to "just exercise more," and that advice often makes things worse. The right movement is gradual, gentle, and respects pacing limits.

Evidence-supported options:

• Aquatic therapy and warm-water pool exercise. The most consistently well-tolerated, with Cochrane-level support for pain, fatigue, and quality-of-life improvement (Bidonde et al., 2017) .
• Tai chi, multiple RCTs show improvement in pain, sleep, and quality of life, including comparative effectiveness data showing tai chi at least matches aerobic exercise for fibromyalgia (Wang et al., 2018) .
• Gentle yoga, particularly restorative styles.
• Walking, started in small increments (5 to 10 minutes) and increased only when stable.
• Strength training at very low intensity, with long rest intervals.

Psychological support

Psychological therapy is not a treatment for the underlying biology, but it helps patients live with the illness more effectively.

• Cognitive Behavioural Therapy (CBT) for chronic pain has good evidence for improving function and reducing the impact of pain. It is not a cure.
• Acceptance and Commitment Therapy (ACT) is increasingly recommended, particularly for patients who have already been through CBT.
• Trauma-informed therapy matters because the rates of childhood adversity and ongoing medical trauma in fibromyalgia patients are high.

What helps versus what harms

Experimental and emerging treatments

Beyond the first-line framework above, patients encounter a wide field of therapies and theories with varying levels of evidence, from "early but promising" to "popular but unproven." Including a treatment here is not an endorsement. The intent is an honest map of what you'll run into, with each entry rated so you can tell what's backed from what's hoped.

Low-Dose Naltrexone (LDN)

Evidence: moderate, growing. Small RCTs at 1.5 to 4.5 mg show meaningful pain reduction (Younger et al., 2013) . The proposed mechanism is anti-neuroinflammatory action on microglia. LDN is well-tolerated, cheap, and increasingly used by integrative and rheumatology clinics, though it remains off-label.

Ketamine infusions

Evidence: limited, mixed. Short-term pain relief is documented but rarely durable. Cost is high. Used at specialised pain clinics rather than as a first-line approach.

Transcranial magnetic stimulation (TMS)

Evidence: emerging. Repetitive TMS to specific brain regions has shown modest improvement in pain and depression in small trials. Available in some specialist clinics.

Vagal nerve stimulation

Evidence: early. Both implanted and non-invasive vagal nerve stimulation have shown effects on inflammation, pain, and autonomic regulation. Active research area.

Hyperbaric oxygen therapy

Evidence: limited but interesting. An Israeli prospective trial showed measurable improvement in pain and brain activity in fibromyalgia patients after a course of HBOT (Efrati et al., 2015) . Replication is partial. Access and cost are significant barriers.

Psychedelics

Evidence: very early. Trials with psilocybin and MDMA for chronic pain and depression are ongoing, with fibromyalgia specifically being studied at MAPS-affiliated sites. Not yet a clinical option.

IVIG (intravenous immunoglobulin)

Evidence: research only. Of interest mainly because of the 2021 autoantibody findings (Goebel et al., 2021) . Very expensive, not currently approved for fibromyalgia.

Neural retraining programs (DNRS, Gupta, ANS Rewire)

Evidence: controversial. These programs frame fibromyalgia as a learned nervous system pattern that can be unlearned through brain retraining, meditation, and visualisation. Anecdotal reports of significant improvement exist. Critics point out that the programs cost thousands of dollars, lack rigorous RCT support, and can reinforce patient self-blame when they do not work. Some patients find genuine benefit. Others feel re-traumatised. Worth approaching with a clear head and reasonable expectations.

Diet-based approaches

Evidence: weak to moderate. Mediterranean diet, anti-inflammatory diets, and individualised elimination diets have modest support. There is no fibromyalgia diet that works for everyone. Severe restriction is usually a bad trade.

Cannabis and CBD

Evidence: mixed. Some patients report meaningful pain and sleep benefit. Others get little. Legal status varies. Drug-drug interactions matter, particularly with SNRIs.

Prognosis

Fibromyalgia is generally chronic. Studies tracking patients over 10+ years find that the majority remain symptomatic, but a meaningful minority improve substantially with treatment, lifestyle changes, and time. Outright remission is uncommon but not impossible, particularly when fibromyalgia was triggered by an identifiable event and treated early.

Recovery and improvement stories

Improvement is more common than full recovery. Patients who improve tend to describe a combination of: figuring out their personal pacing baseline, finding a medication that works for them, fixing their sleep, finding the right movement, addressing comorbid conditions (especially sleep apnea, POTS, and mental health), and building a life with margin built in.

Self-directed care

Because most healthcare systems are poorly set up to manage chronic, multisymptom conditions, fibromyalgia patients become their own case managers. They learn to track symptoms, advocate in appointments, manage medication side effects, coordinate between specialists, and educate the people in their lives. This is exhausting, and it is necessary.

Daily functioning

• Mornings are often worse. Stiffness, pain, and fog are usually highest within the first hour or two of waking. Schedules that demand peak performance at 8 am are misaligned with this reality.
• Sustained postures cost more than they should. Sitting at a desk for two hours can produce as much fatigue as a workout in a healthy person.
• Weather and barometric pressure shift symptoms for many patients. Not all patients, but enough to take seriously.
• Menstrual cycles influence symptoms in most menstruating patients. Premenstrual and menstrual weeks tend to be worse.

The crash after a normal day out

Hormonal issues

Perimenopause is often the period of the most significant symptom worsening, sometimes the period when fibromyalgia first emerges clinically. The interplay between fluctuating oestrogen, sleep disruption, and central sensitisation is real and under-studied. Patients in perimenopause should be evaluated for hormone-related interventions in parallel with fibromyalgia care.

Skin-related symptoms

The skin can be unusually sensitive, sometimes flushed (livedo reticularis), sometimes mottled, often hypersensitive to fabrics, seams, and tight clothing. Dry skin and dry eyes (sicca symptoms) are common. Bra straps, in particular, come up over and over in patient communities as a back-pain trigger that clinicians rarely ask about.

Work, disclosure, and disability

The labour market is not a level playing field for invisible illness. Disclosing fibromyalgia during a job application frequently triggers rejection, framed, of course, as unrelated to the disability.

On the disability side, a US federal court ruling in December 2025 confirmed that the Social Security Administration cannot dismiss fibromyalgia claims solely because objective tests are normal. Worth knowing about for anyone navigating SSDI.

Adapting life around the illness

The patients who do best with fibromyalgia tend to redesign their lives around it rather than fight it. That can mean a different career, a different schedule, less travel, fewer commitments, more rest, more transparency with employers and friends, and a slower rhythm overall. The cultural pressure to "push through" is one of the most damaging forces in fibromyalgia, and unlearning it is part of treatment.

Fibromyalgia rarely travels alone. Most patients meet criteria for at least one other condition. Understanding the overlap matters because treating only fibromyalgia, while leaving a comorbid condition untreated, leaves people stuck.

This is visible to patients well before it shows up in medical training. The same cluster keeps surfacing in adjacent disease communities:

ME/CFS

Roughly 30 to 70% of fibromyalgia patients also meet criteria for ME/CFS, depending on which criteria are used. The defining feature of ME/CFS is post-exertional malaise (PEM): a delayed, disproportionate worsening of all symptoms after exertion, often lasting days or weeks. Patients with significant PEM should be treated with extra caution around exercise programs, and Graded Exercise Therapy is contraindicated (NICE, 2021) .

POTS and dysautonomia

POTS (Postural Orthostatic Tachycardia Syndrome) is diagnosed when the heart rate increases by 30 bpm (40 in adolescents) within 10 minutes of standing, without a drop in blood pressure. It causes dizziness, lightheadedness, brain fog, fatigue, and chest discomfort. Up to a third of fibromyalgia patients have POTS or another form of dysautonomia. A tilt-table test can confirm.

Long COVID

Long COVID has produced a wave of new fibromyalgia and fibromyalgia-like presentations. The overlap is clinically obvious and biologically plausible: viral trigger, neuroinflammation, autonomic dysfunction, post-exertional malaise (Davis et al., 2023) . Many Long COVID clinics now use fibromyalgia and ME/CFS protocols as their starting point.

Mast Cell Activation Syndrome (MCAS)

MCAS is increasingly recognised in the chronic illness cluster. Symptoms include flushing, hives, GI distress, food and drug sensitivities, and dramatic reactions to histamine triggers. Patients who do not respond to fibromyalgia treatment as expected, especially those with strong food and environmental sensitivities, are worth evaluating for MCAS.

Small Fibre Neuropathy

40 to 50% of fibromyalgia patients have reduced small nerve fibre density on skin biopsy (Oaklander et al., 2013) . This is not a separate illness so much as a peripheral marker of the central nervous system dysfunction in fibromyalgia. It does, however, confirm a biological substrate for the burning, electric, neuropathic pain that many patients describe.

IBS and GI dysmotility

30 to 70% comorbidity. Often pre-dates the fibromyalgia diagnosis. The gut-brain axis is a shared mechanism.

Migraine

Roughly 35 to 55% of fibromyalgia patients have chronic migraine. Both are central sensitisation conditions. Treating one often improves the other.

Endometriosis

The overlap is significant in menstruating patients, with shared mechanisms in pelvic pain processing. Patients with severe menstrual pain should be evaluated for endometriosis even when a fibromyalgia diagnosis is in place.

Ehlers-Danlos Syndrome (EDS)

Hypermobile EDS, in particular, shows up alongside fibromyalgia at well above population rates. EDS, POTS, and MCAS form a triad now widely discussed in chronic illness research. The clue that frequently goes uninvestigated:

Mood and anxiety disorders

30 to 60% prevalence for depression and anxiety. Treating these as natural consequences of living with chronic, dismissed pain, rather than as the cause of the fibromyalgia, leads to better outcomes.

Sjögren's, UCTD, and the autoimmune adjacent

Sjögren's syndrome, characterised by dry eyes, dry mouth, fatigue, and joint pain, overlaps with fibromyalgia at well above population rates (Theander et al., 2015) . Many patients are diagnosed with fibromyalgia first, then with Sjögren's years later when sicca symptoms become impossible to ignore. ANA, anti-Ro/SSA, and anti-La/SSB testing belong in any workup where dry eyes or dry mouth are prominent.

Undifferentiated Connective Tissue Disease (UCTD) is the diagnosis some patients receive when they don't quite meet criteria for lupus, Sjögren's, or RA but have inflammatory markers and clear immune-driven features. UCTD often responds to hydroxychloroquine (Plaquenil) where pure fibromyalgia doesn't.

Sleep apnea (under-diagnosed, high-impact)

Obstructive sleep apnea co-occurs with fibromyalgia more often than chance, and untreated sleep apnea can produce fibromyalgia-like symptoms on its own. The combination is brutal: amplified pain signalling plus a brain that never gets enough oxygen at night.

A sleep study (home or in-lab) is worth doing even if you don't snore. Restless sleep, morning headaches, and "waking unrefreshed despite eight hours" all justify it. CPAP doesn't always rescue fibro sleep on its own, there are usually multiple drivers, but for the subset where apnea is the dominant cause, treating it can change the disease.

Pelvic floor dysfunction

Central sensitisation extends to the pelvic muscles. The result: pelvic pain, urinary urgency, painful intercourse, incontinence on coughing or sneezing, constipation, and low-back-meets-tailbone pain that doesn't respond to standard back-pain interventions (Verra et al., 2018) . Pelvic-floor physical therapy is the gold-standard intervention, most patients don't know it exists.

ADHD, autism, and AuDHD

Neurodivergence and fibromyalgia co-occur at well above population rates. Patients with autism spectrum, ADHD, or both ("AuDHD") report disproportionately intense flares, pain plus sensory overwhelm together, and often have a harder time noticing their early flare signs because interoception (the sense of one's own body) is already atypical.

If you've been told you have "fibro fog" and you're starting to wonder whether it's also ADHD, get evaluated. Treating one improves the other.

Trauma, PTSD, and complex PTSD

Adverse childhood experiences (ACE) are over-represented in fibromyalgia patient histories, a meta-analysis of 18 studies confirmed significantly higher rates of childhood emotional, physical, and sexual abuse in fibromyalgia patients vs controls (Häuser et al., 2011) . The foundational ACE Study established the broader dose-response link between childhood adversity and adult chronic disease (Felitti et al., 1998) . So are adult traumas, sexual assault, prolonged abuse, combat, severe medical procedures.

The honest reading of the evidence: trauma is one of several drivers that can prime the nervous system into the pain-amplification state. Naming it does not mean the illness is psychological, it means the illness has a layer that talk therapy, somatic work, EMDR, or trauma-informed care can meaningfully address alongside medical treatment.

Other overlaps

• Temporomandibular joint disorder (TMJ)
• Interstitial cystitis / bladder pain syndrome
• Restless legs syndrome
• Raynaud's phenomenon
• Hashimoto's thyroiditis
• PCOS (polycystic ovary syndrome)
• Lupus / RA / ankylosing spondylitis (when present, drive their own workup, not always either/or with fibro)
• Lyme disease and other tick-borne infections (regionally)

The current biological picture

Fibromyalgia is best understood today as a disorder of central nervous system pain processing, with peripheral nervous system involvement in a substantial subset, low-grade neuroinflammation, autonomic dysregulation, and a possible autoimmune component. Each of these is supported by independent lines of evidence (Gracely et al., 2002) (Oaklander et al., 2013) (Albrecht et al., 2019) (Goebel et al., 2021) .

Historical timeline

Recent findings worth knowing

Two results from the last 18 months are reshaping how the field thinks about fibromyalgia.

2025: A genetic architecture, finally

A large genome-wide association study identified 26 genetic risk loci for fibromyalgia, with the strongest signal on the HTT gene and clear effects on neurotransmitter pathways and brain development (Rahman et al., 2025) . The implication: fibromyalgia has a measurable hereditary component, and it isn't a single disease, it's a phenotype with multiple genetic routes in.

2026: A measurable brain fingerprint of pain

An fMRI + machine-learning study showed that fibromyalgia pain produces a measurable, individualised pattern of brain connectivity, each person's pain "looks" different, but each pattern is consistent enough that a model can predict pain severity from connectivity alone. It's the clearest objective demonstration to date that the pain is real, measurable, and biologically personalised.

Active research directions

• Autoimmune fibromyalgia subtype. Follow-up to Goebel and colleagues' 2021 work, looking for the specific autoantibody targets.
• Glial cell modulators. Drugs targeting microglial activation, including LDN and newer compounds.
• Wearable biomarkers. HRV, sleep architecture, and autonomic patterns as objective markers of flare risk and treatment response. Devices like the Visible armband (commercial), Oura, Apple Watch, and Whoop are increasingly used in patient communities for pacing.
• Subtyping. Increasing evidence that fibromyalgia is not one disease but several biological subtypes that look similar clinically. Subtyping may eventually drive personalised treatment.
• Gut microbiome. Studies show altered microbiome composition in fibromyalgia patients. Causality is still unclear.

Key papers worth reading

• Goebel et al. (2021), Journal of Clinical Investigation. The autoantibody transfer study (Goebel et al., 2021) .
• Albrecht et al. (2019), Brain, Behavior, and Immunity. Neuroinflammation PET imaging (Albrecht et al., 2019) .
• Clauw (2014), JAMA. The clinical review that shaped a generation of physicians' understanding (Clauw, 2014) .
• Oaklander et al. (2013), Pain. Small fibre neuropathy findings (Oaklander et al., 2013) .
• Gracely et al. (2002), Arthritis & Rheumatism. The original fMRI pain processing study (Gracely et al., 2002) .

Resources and community

Advocacy and education organisations

• National Fibromyalgia Association (US). Patient education, advocacy, awareness campaigns.
• Support Fibromyalgia Network. Patient-led education and community.
• Fibromyalgia Action UK. UK-based charity, helpline, and local groups.
• American College of Rheumatology. The authoritative source for diagnostic criteria.
• European Alliance of Associations for Rheumatology (EULAR). Maintains the European management guidelines.
• International Association for the Study of Pain (IASP). The body that formalised the nociplastic pain category.
• ME Action. Particularly relevant for patients with significant ME/CFS overlap.
• Open Medicine Foundation. Funds post-viral and central-sensitisation research; runs a fibromyalgia / ME/CFS / Long COVID register.
• Dysautonomia International. For POTS and broader autonomic dysfunction support.

Books worth reading

• The Fibro Manual, Ginevra Liptan, MD. Practical management, written by a clinician who also has fibromyalgia. Companion podcast / YouTube channel: The Fibro Show.
• The Pain Management Workbook, Rachel Zoffness. CBT-and-ACT for chronic pain, in a fillable workbook format.
• Get a Life, Chloe Brown, Talia Hibbert. One of the few mainstream novels with an accurate chronic-pain protagonist. Frequently recommended in patient communities for the "I felt seen" effect.
• The Body Keeps the Score, Bessel van der Kolk. The standard reference on trauma and the body. Relevant to the trauma-as-driver subset.
• How to Be Sick, Toni Bernhard. Buddhist-informed essays on building a life around chronic illness.

Podcasts and creators

• The Fibro Show (Ginevra Liptan). Patient-clinician format with practical management depth.
• Nothing Much Happens. Not a fibro podcast, twice-told sleep stories. The single most-recommended non-pharmacological sleep aid in fibro communities.
• The Cure for Chronic Pain (Nicole Sachs). Mind-body / TMS framework; controversial but a meaningful subset find genuine benefit.
• Jessica Kellgren-Fozard (YouTube). Long-running chronic illness creator covering accessibility, accommodations, and life with multiple chronic conditions.

Clinical trials and research participation

• ClinicalTrials.gov, search "fibromyalgia" filtered to "recruiting" to find currently enrolling studies.
• EU Clinical Trials Register, equivalent for European studies.
• You + ME Registry (Open Medicine Foundation), patient-contributed data registry for ME/CFS, Long COVID, and overlapping conditions.

Online community spaces

Patient communities, particularly r/Fibromyalgia on Reddit, condition-specific Facebook groups (work, parenting, perimenopause, comorbidities), and Discord servers organised by severity, are some of the most valuable resources patients have. They are also where misinformation, supplement marketing, and pseudoscience can spread fastest. Approach with the same critical thinking you would apply to any source.

Content creators worth following

These are the names that come up again and again in the fibro / ME/CFS / Long COVID corners of Reddit, sorted by what the community actually shares, not by who happens to make videos. The Reddit citation under each card is the thread the recommendation traces back to, so you can see why they're trusted, not just that they are.

YouTube

Podcasts

Research & journalism

References

Every claim in this reference is linked to a peer-reviewed paper, guideline, or systematic review. Each entry below includes a one-line annotation explaining what the paper showed and why we cite it.

1. Gracely RH, Petzke F, Wolf JM, Clauw DJ (2002). Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis & Rheumatism, 46(5), 1333–1343.

   Landmark fMRI study showing fibromyalgia patients activate pain-processing brain regions in response to pressure that healthy controls describe as only mildly uncomfortable. First major objective evidence for central sensitisation.

   DOI: 10.1002/art.10225 PubMed: 12115241

2. Clauw DJ (2014). Fibromyalgia: a clinical review. JAMA, 311(15), 1547–1555.

   The clinical review that shaped a generation of physicians' understanding of fibromyalgia as a central sensitisation disorder. Still the most readable introduction for clinicians.

   DOI: 10.1001/jama.2014.3266 PubMed: 24737367

3. Oaklander AL, Herzog ZD, Downs HM, Klein MM (2013). Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain, 154(11), 2310–2316.

   First-of-its-kind skin-biopsy study showing roughly 40% of fibromyalgia patients have reduced small nerve fibre density. Provided a peripheral biological substrate for the burning, electric pain patients describe.

   DOI: 10.1016/j.pain.2013.06.001 PubMed: 23748113

4. Albrecht DS, Forsberg A, Sandström A, et al. (2019). Brain glial activation in fibromyalgia, A multi-site positron emission tomography investigation. Brain, Behavior, and Immunity, 75, 72–83.

   Multi-site PET imaging study from MGH/Karolinska showing widespread glial cell activation across the brain in fibromyalgia patients, the strongest objective evidence to date of low-grade neuroinflammation.

   DOI: 10.1016/j.bbi.2018.09.018 PubMed: 30223011

5. Goebel A, Krock E, Gentry C, Israel MR, Jurczak A, Urbina CM, et al. (2021). Passive transfer of fibromyalgia symptoms from patients to mice. Journal of Clinical Investigation, 131(13), e144201.

   The autoantibody transfer study. IgG antibodies from fibromyalgia patients, when injected into mice, produced fibromyalgia-like pain sensitivity and reduced movement. The strongest evidence to date for an autoimmune contribution in at least a subset of patients.

   DOI: 10.1172/JCI144201 PubMed: 34196305

6. Kosek E, Cohen M, Baron R, et al. (2016). Do we need a third mechanistic descriptor for chronic pain states?. Pain, 157(7), 1382–1386.

   The paper that argued for nociplastic pain as a third mechanistic category alongside nociceptive and neuropathic pain. Foundation for the IASP's formal 2017 recognition with fibromyalgia as the canonical example.

   DOI: 10.1097/j.pain.0000000000000507 PubMed: 26835783

7. Wolfe F, Clauw DJ, Fitzcharles MA, et al. (2016). 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 46(3), 319–329.

   The current diagnostic criteria for fibromyalgia (WPI ≥7 with SSS ≥5, or WPI 4–6 with SSS ≥9; generalised pain ≥3 months; valid in the presence of other diagnoses).

   DOI: 10.1016/j.semarthrit.2016.08.012 PubMed: 27916278

8. National Institute for Health and Care Excellence (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). NICE Guideline NG206.

   The NICE guideline that formally repudiated graded exercise therapy (GET) as historically practised for ME/CFS, and by extension for patients with significant post-exertional malaise overlap, including many with fibromyalgia.

   Source

9. Efrati S, Golan H, Bechor Y, Faran Y, Daphna-Tekoah S, Sekler G, et al. (2015). Hyperbaric oxygen therapy can diminish fibromyalgia syndrome, Prospective clinical trial. PLOS ONE, 10(5), e0127012.

   Israeli prospective trial showing measurable improvement in pain and brain activity in fibromyalgia patients after a course of hyperbaric oxygen therapy. Replication is partial; access and cost remain barriers.

   DOI: 10.1371/journal.pone.0127012 PubMed: 25996650

10. Doebl S, Macfarlane GJ, Hollick RJ (2020). 'No one wants to look after the fibro patient'. Understanding models, and patient perspectives, of care for fibromyalgia. Pain, 161(8), 1716–1725.

    Qualitative study documenting fibromyalgia patients' experiences of clinician dismissal and the orphan status of fibromyalgia within healthcare systems. A representative anchor for the medical-gaslighting literature.

    DOI: 10.1097/j.pain.0000000000001870 PubMed: 32287147

11. Häuser W, Ablin J, Perrot S, Fitzcharles MA (2017). Management of fibromyalgia: practical guides from recent evidence-based guidelines. Polish Archives of Internal Medicine, 127(1), 47–56.

    Practical synthesis of the EULAR, Canadian and German evidence-based fibromyalgia management guidelines, emphasising multimodal non-pharmacological care, education, and graded movement individualised to the patient.

    DOI: 10.20452/pamw.3877 PubMed: 28075425

12. Younger J, Noor N, McCue R, Mackey S (2013). Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis & Rheumatism, 65(2), 529–538.

    Small randomised crossover trial showing meaningful pain reduction with low-dose naltrexone in fibromyalgia, with the proposed mechanism being anti-neuroinflammatory action on microglia.

    DOI: 10.1002/art.37734 PubMed: 23359310

13. Wang C, Schmid CH, Fielding RA, et al. (2018). Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ, 360, k851.

    Pragmatic RCT showing tai chi at least as effective as aerobic exercise for fibromyalgia symptom improvement, with longer-duration tai chi producing larger benefit. One of the cleanest movement-intervention RCTs in the field.

    DOI: 10.1136/bmj.k851 PubMed: 29563100

14. Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG (2020). Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Journal of Translational Medicine, 18(1), 100.

    Global prevalence meta-analysis for ME/CFS, included here because so many fibromyalgia patients also meet ME/CFS criteria, useful when discussing the overlap and the central sensitivity cluster.

    DOI: 10.1186/s12967-020-02269-0 PubMed: 32093722

15. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, et al. (2017). EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases, 76(2), 318–328.

    European League Against Rheumatism revised recommendations, current authoritative management guideline. Multimodal non-pharmacological care first, with medications and other interventions added as needed.

    DOI: 10.1136/annrheumdis-2016-209724 PubMed: 27377815

16. Heidari F, Afshari M, Moosazadeh M (2017). Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatology International, 37(9), 1527–1539.

    Systematic review of fibromyalgia prevalence across populations, supporting the commonly-cited 2–4% global adult prevalence figure with country-by-country breakdowns.

    DOI: 10.1007/s00296-017-3725-2 PubMed: 28447207

17. Moldofsky H, Scarisbrick P, England R, Smythe H (1975). Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosomatic Medicine, 37(4), 341–351.

    Classic study identifying alpha-wave intrusion into delta (deep) sleep in fibromyalgia patients and demonstrating that sleep disruption alone can produce fibromyalgia-like symptoms in healthy controls.

    DOI: 10.1097/00006842-197507000-00008 PubMed: 169541

18. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, et al. (2013). Small fibre pathology in patients with fibromyalgia syndrome. Brain, 136(6), 1857–1867.

    Independent replication of small-fibre nerve pathology in fibromyalgia using both skin biopsy and quantitative sensory testing, confirming the Oaklander 2013 findings in a European cohort.

    DOI: 10.1093/brain/awt053 PubMed: 23474848

19. Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E (2010). A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Services Research, 10, 102.

    International patient survey documenting the average ~5-year delay from symptom onset to fibromyalgia diagnosis and the multiple clinician visits required, a primary source for the diagnostic-delay statistics on this page.

    DOI: 10.1186/1472-6963-10-102 PubMed: 20420681

20. Häuser W, Kosseva M, Üçeyler N, Klose P, Sommer C (2011). Emotional, physical, and sexual abuse in fibromyalgia syndrome, a systematic review with meta-analysis. Arthritis Care & Research, 63(6), 808–820.

    Meta-analysis confirming significantly higher rates of childhood emotional, physical, and sexual abuse in fibromyalgia patients vs controls. Provides the evidence base for the trauma-as-driver framing in the comorbidities chapter.

    DOI: 10.1002/acr.20328 PubMed: 20722042

21. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, et al. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults, The Adverse Childhood Experiences (ACE) Study. American Journal of Preventive Medicine, 14(4), 245–258.

    The foundational ACE Study establishing the dose–response relationship between childhood adversity and adult chronic disease. Cited for the broader framework around childhood trauma and central sensitisation.

    DOI: 10.1016/S0749-3797(98)00017-8 PubMed: 9635069

22. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A (2017). A framework for the classification of joint hypermobility and related conditions. American Journal of Medical Genetics Part C, 175(1), 148–157.

    The international consensus framework that codified the hypermobile EDS, POTS, MCAS triad now widely recognised as overlapping with fibromyalgia.

    DOI: 10.1002/ajmg.c.31539 PubMed: 28145606

23. Davis HE, McCorkell L, Vogel JM, Topol EJ (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133–146.

    Comprehensive review of Long COVID mechanisms and clinical features, including the substantial overlap with ME/CFS and fibromyalgia. Anchors the Long COVID comorbidity subsection on this page.

    DOI: 10.1038/s41579-022-00846-2 PubMed: 36639608

24. Bidonde J, Busch AJ, Schachter CL, Overend TJ, Kim SY, et al. (2017). Aerobic exercise training for adults with fibromyalgia. Cochrane Database of Systematic Reviews, 6, CD012700.

    Cochrane systematic review supporting low-to-moderate intensity aerobic exercise, particularly aquatic, as effective for pain, fatigue, and quality of life in fibromyalgia.

    DOI: 10.1002/14651858.CD012700 PubMed: 28636204

25. Lunn MPT, Hughes RAC, Wiffen PJ (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews, 1, CD007115.

    Cochrane review of duloxetine across painful neuropathy and fibromyalgia, establishing efficacy at 60 mg/day. Supports the medication framework on this page.

    DOI: 10.1002/14651858.CD007115.pub3 PubMed: 24385423

26. Antcliff D, Keeley P, Campbell M, Woby S, McGowan L, Oldham J (2018). Activity pacing: moving beyond taking breaks and slowing down. Quality of Life Research, 27(7), 1933–1935.

    Conceptual paper distinguishing modern activity-pacing methods from the older 'just rest' framing. Underpins the pacing-protocols subsection (heart-rate ceiling, time-budget blocks, energy envelope).

    DOI: 10.1007/s11136-018-1794-7 PubMed: 29397500

27. Henssler J, Heinz A, Brandt L, Bschor T (2019). Antidepressant withdrawal and rebound phenomena, a systematic review. Deutsches Ärzteblatt International, 116(20), 355–361.

    Systematic review documenting antidepressant discontinuation syndromes, including the SNRI-specific 'brain zaps' and prolonged symptom profile. Supports the SNRI taper warning in the medications section.

    DOI: 10.3238/arztebl.2019.0355 PubMed: 31288917

28. Theander L, Strömbeck B, Mandl T, Theander E (2015). Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome?. Rheumatology, 54(10), 1722–1729.

    Documents the high overlap between primary Sjögren's syndrome and fibromyalgia-like fatigue/pain syndromes, supports the Sjögren's/UCTD comorbidity subsection on this page.

    DOI: 10.1093/rheumatology/keu539 PubMed: 25618614

29. Verra ML, Angst F, Brioschi R, Lehmann S, Aeschlimann A (2018). Pelvic floor dysfunction in patients with chronic widespread pain and fibromyalgia. International Urogynecology Journal, 29(11), 1655–1661.

    Prospective study confirming high prevalence of pelvic-floor dysfunction in fibromyalgia patients and the value of pelvic-floor physical therapy. Supports the pelvic-floor comorbidity section.

    DOI: 10.1007/s00192-018-3622-6 PubMed: 29445827

30. Rahman MS, et al. (2025). Genetic Architecture of Fibromyalgia across 2.5 million Individuals. MedRxiv (preprint).

    GWAS preprint identifying 26 genetic risk loci for fibromyalgia across a 2.5-million-person cohort, with the strongest signal on the HTT gene and implications for neurotransmitter and brain-development pathways. Anchors the 2025 finding in the timeline and recent-findings section.

    DOI: 10.1101/2025.10.01.25337842 Source

31. Krock E, Morado-Urbina CE, Menezes J, Hunt MA, Sandström A, et al. (2023). Fibromyalgia patients have an autoantibody-driven amplification of pain signaling. Journal of Clinical Investigation, 133(13), e166635.

    Follow-up to Goebel 2021, characterises the satellite-glial-cell IgG targets in fibromyalgia patient antibodies and further supports an autoimmune contribution in a subset.

    DOI: 10.1172/JCI166635 PubMed: 37183833

32. Ablin JN, Buskila D, Clauw DJ (2013). Biomarkers in fibromyalgia. Current Pain and Headache Reports, 17(11), 374.

    Review of biomarker candidates in fibromyalgia (HRV, autonomic measures, cytokines, neuroimaging), the conceptual basis for wearable-data interpretation tools like Rox.

    DOI: 10.1007/s11916-013-0374-3 PubMed: 24078017

About this reference

This is a living document. It will be updated as new research emerges and as patients tell us what is missing. If you spot an error, want to suggest an addition, or have a story you would like considered for inclusion, we want to hear from you.